Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 11/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 6/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8808441 | 0.83 | ALDH1A1 (0.38) | S1PR4SMN1; SMN2MAPTLMNATSHR | |
| SCHEMBL4833523 | 0.78 | TSHR (0.34) | S1PR4NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4829296 | 0.75 | S1PR4 (0.39) | S1PR4NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL15716302 | 0.73 | NPC1 (0.46) | S1PR4NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5267218 | 0.72 | MAPT (0.41) | NPC1RAB9ASMN1; SMN2MAPTLMNA | |
| SCHEMBL4829285 | 0.71 | MAPT (0.38) | S1PR4SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL19171827 | 0.70 | TSHR (0.38) | S1PR4NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL19173076 | 0.68 | SMN1; SMN2 (0.49) | S1PR4SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL14910676 | 0.65 | ALDH1A1 (0.42) | NPC1RAB9ASMN1; SMN2MAPTLMNA | |
| SCHEMBL15716355 | 0.65 | S1PR4 (0.40) | S1PR4NPC1SMN1; SMN2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1627875-B1 | METHOD FOR PRODUCING CYCLIC DIAMINE DERIVATIVE OR SALT THEREOF | KOWA CO (JP) | 2013-07-31 | — | — | EP | disclosed |
| US-7459552-B2 | Method for producing cyclic diamine derivative or salt thereof | KOWA CO., LTD. (JP) | 2008-12-02 | — | — | US | disclosed |
| US-20060293519-A1 | Method for producing cyclic diamine derivative or salt thereof | KOWA CO., LTD. (JP) | 2006-12-28 | — | — | US | disclosed |
| EP-1627875-A1 | METHOD FOR PRODUCING CYCLIC DIAMINE DERIVATIVE OR SALT THEREOF | Kowa Co., Ltd. (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293519-A1 | Method for producing cyclic diamine derivative or salt thereof | NNT, APRT, SAT1 | S1PR4 1248/4885NPC1 1124/4885RAB9A 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.